Spirocyclic heterocyclic derivatives and methods of their use

Details Spirocyclic heterocyclic derivatives and methods of their use Spirocyclic heterocyclic derivatives and methods of their use

2006-03-30

2009-10-06

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S017000, C544S124000, C514S232800

Reexamination Certificate

active

07598261

ABSTRACT:
Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

REFERENCES:
patent: 5106998 (1992-04-01), Tanaka et al.
patent: 5132307 (1992-07-01), Baumgarth et al.
patent: 5349065 (1994-09-01), Tanaka et al.
patent: 5354863 (1994-10-01), Dappen et al.
patent: 5356915 (1994-10-01), Almansa et al.
patent: 5387587 (1995-02-01), Häusler et al.
patent: 5403846 (1995-04-01), Baldwin et al.
patent: 5628935 (1997-05-01), Hughes et al.
patent: 5656420 (1997-08-01), Chien
patent: 5705102 (1998-01-01), Hughes et al.
patent: 5786378 (1998-07-01), Hamilton et al.
patent: 5990131 (1999-11-01), Hamilton et al.
patent: 6031115 (2000-02-01), Bell et al.
patent: 6040308 (2000-03-01), Häusler et al.
patent: 6153627 (2000-11-01), Häusler et al.
patent: 6200978 (2001-03-01), Maw et al.
patent: 6218424 (2001-04-01), Hamilton et al.
patent: 6319939 (2001-11-01), Mabire et al.
patent: 6417209 (2002-07-01), Hamilton et al.
patent: 6436959 (2002-08-01), Carson et al.
patent: 6596758 (2003-07-01), Brunet et al.
patent: 6645973 (2003-11-01), Gibson et al.
patent: 7338962 (2008-03-01), Dolle et al.
patent: 2001/0056103 (2001-12-01), Hamilton et al.
patent: 2002/0115653 (2002-08-01), Mabire et al.
patent: 2002/0193420 (2002-12-01), Hamilton et al.
patent: 2003/0069241 (2003-04-01), Mchardy et al.
patent: 2004/0082612 (2004-04-01), Baxter et al.
patent: 2004/0106652 (2004-06-01), Hamilton et al.
patent: 2005/0159438 (2005-07-01), Dolle et al.
patent: 0 420 266 (1991-04-01), None
patent: 0 362 119 (1993-07-01), None
patent: 0 600 147 (1994-06-01), None
patent: 0 401 958 (1995-01-01), None
patent: 0 376 524 (1995-03-01), None
patent: 0 708 164 (1996-04-01), None
patent: 0 582 338 (1999-10-01), None
patent: 1 179 551 (2002-02-01), None
patent: 0 864 559 (2002-06-01), None
patent: 4-275288 (1992-09-01), None
patent: 9-301973 (1997-11-01), None
patent: 93/17026 (1993-09-01), None
patent: 93/19755 (1993-10-01), None
patent: 94/17045 (1994-08-01), None
patent: WO 95/04734 (1995-02-01), None
patent: WO 95/31464 (1995-11-01), None
patent: WO 96/22276 (1996-07-01), None
patent: WO 97/10216 (1997-03-01), None
patent: 99/04795 (1999-02-01), None
patent: 99/29674 (1999-06-01), None
patent: 00/39113 (2000-07-01), None
patent: 01/36423 (2001-05-01), None
patent: WO 01/46192 (2001-06-01), None
patent: 01/83476 (2001-11-01), None
patent: WO 02/48122 (2002-06-01), None
patent: 02/094782 (2002-11-01), None
patent: WO 02/094783 (2002-11-01), None
patent: WO 02/094784 (2002-11-01), None
patent: WO 02/094785 (2002-11-01), None
patent: WO 02/094786 (2002-11-01), None
patent: WO 02/094794 (2002-11-01), None
patent: WO 02/094810 (2002-11-01), None
patent: WO 02/094811 (2002-11-01), None
patent: WO 02/094812 (2002-11-01), None
patent: WO 03/029215 (2003-04-01), None
patent: WO 03/033486 (2003-04-01), None
patent: WO 03/037342 (2003-05-01), None
patent: WO 03/057223 (2003-07-01), None
patent: WO 93/15062 (2003-08-01), None
patent: WO2004/026819 (2004-04-01), None
patent: WO2004/035541 (2004-04-01), None
patent: WO2004/035574 (2004-04-01), None
patent: WO2004/041784 (2004-05-01), None
patent: WO2004/041800 (2004-05-01), None
patent: WO2004/041801 (2004-05-01), None
patent: WO2004/041802 (2004-05-01), None
patent: WO2004/060321 (2004-07-01), None
patent: WO2004/062562 (2004-07-01), None
patent: WO2004/063157 (2004-07-01), None
patent: WO2004/063193 (2004-07-01), None
patent: 2004/082612 (2004-09-01), None
patent: 2005/033073 (2005-04-01), None
Bhargava, H.N., et al., “Effect of nitric oxide synthase inhibition on tolerance to the analgesic action of D-Pen2, D-Pen5enkephalin and morphine in the mouse,”Neuropeptides, 1996, 30(3), 219-223.
Bilsky, E.J., et al., “SNC 80, a selective, nonpeptidic and systemically active opioiddeltaagonist,”J. of Pharmacology and Experimental Therapeutics, 1995, 273(1), 359-366.
Bilsky, E.J., et al., “Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice,”J. of Pharmacol Exp. Ther., 1996, 277(1), 484-490.
Borlongan, C.V., et al., “Delta opioid peptide (D-ALA 2, D-LEU 5) enkephalin: linking hibernation and neuroprotection,”Frontiers in Bioscience, 2004, 9(Suppl.), 3392-3398.
DeHaven R.N., et al., “Characterization of opioid receptors,”Current Protocols in Pharmacology, 2000,John Wiley&Sons, 1.4.1-1.4.12.
Dondio, et al., “Central & peripheral nervous systems: non-peptide δ opioid agonists and antagonists,”Exp. Opin. Ther. Patents, 1997, 7(10), 1075-1098.
Dourish, C.T., et al., “Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364, 718,”Eur. J. Pharmacol., 1988, 147, 469-472.
Fraser, M.O., “Urinary incontinence: neuropharmacological approaches,”Annual Reports in Medicinal Chemistry, 2003, Chapter 6, 51-60.
Galligan, J.J., et al., “Cerebraldeltaopioid receptors mediate analgesia but not the intestinal motility effects of intracerebroventicularly administered opioids,”J. Pharm. Exp. Ther., 1984, 229(3), 641-648.
Jain, K.K., “A guide to drug evaluation for chronic pain,”Emerging Drugs, 2000, 5(2), 241-257.
Lord, J.A.H., et al., “Endogenous opioid peptides: multiple agonists and receptors,”Nature, 1977, 267, 495-499.
Mao, M.J., et al., “Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats,”Pain, 1996, 67, 361-368.
Moreland, R.B., et al., “Emerging pharmacologic approaches for the treatment of lower urinary tract disorders,”Perspectives in Pharmacology, 2004, 308(3), 797-804.
Moulin, D.E., et al., The analgesic efficacy of intrathecal D-Ala2-D-Leu5.Pain, 1985, 23, 213-221.
Nichols, M.L., et al., “Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy,”Pain, 1997, 69, 317-322.
Raynor, K., et al., “Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors,”Molecular Pharmacology, 1994, 45, 330-334.
Su, T.-P., “Delta opioid peptide [D-Ala2,D-Leu5]enkephalin promotes cell survival,”J. of Biomedical Science, 2000, 7, 195-199.
U.S. Appl. No. 60/507,864, filed Oct. 1, 2003, Roland Dolle.
U.S. Appl. No. 10/957,554, filed Oct. 1, 2004, Roland Dolle.
Dorland's Illustrated Medical Dictionary, 27thEd.,W.B. Saunders co., Phila., 1988, p. 375.
Livingston, E.H., et al., “Postoperative Ileus,”Digestive Diseases and Sciences, 1990, 35(1), 121-132.
Resnick, J., “Delayed gastric emptying and postoperative Ileus after nongastric abdominal surgery: Part I,”Am. J. of Gastroenterology, 1997, 92(5), 751-762.
Resnick, J., “Delayed gastric emptying and postoperative Ileus after nongastric abdominal surgery: Part II,”Am. J. of Gastroenterology, 1997, 92(6), 934-940.
Schultz, J.J. et al, “Ischemic Preconditioning and Morphine-Induced Cardioprotection Involve the delta-Opioid Receptor in the Intact Rat Heart”,J. Mol. Cell. Cardiol., 1997, 29, 2187-2195.
Schultz, J.J. et al., “Ischemic Preconditioning is Mediated by a Peripheral Opioid Receptor Mechanism in the Intact Rat Heart”,J. Mol. Cell. Cardiol., 1997, 29, 1355-1362.
Tsung-Ping Su, “Delta Opioid Peptide [D-Ala2,D-Leu5]Enkephalin Promotes Cell Survival,”J. of Biomedical Science, 2000, 7, 195-199.
Watson, M.J. et al., “ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimet

Affiliated with

Also associated with

Rating

Spirocyclic heterocyclic derivatives and methods of their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Spirocyclic heterocyclic derivatives and methods of their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirocyclic heterocyclic derivatives and methods of their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4094393